Stock SABS SAB BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

Market Closed - Nasdaq
Other stock markets
 02:00:01 04/05/2024 am IST 		5-day change 1st Jan Change
4.03 USD +0.25% Intraday chart for SAB Biotherapeutics, Inc. -5.17% -41.38%
16/04 SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update CI
02/04 HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating MT

Evolution of the average Target Price on SAB Biotherapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

19d3486c345497b35e1856a078a17.HPJcyuFpumV6n4G2dvJQQOa1YyOp-Mgo87VJqbq1Lk4.dsIT_5ZbzlUP2LnQD54bH5TFPHv_zoJvqYM79tT_Z3clgTSS0ljZFTCt4g~42ae1428df67f6ebc7b0dbe3153e57f9

Analyst Recommendations on SAB Biotherapeutics, Inc.

HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating MT
HC Wainwright Trims SAB Biotherapeutics' Price Target to $1 From $2, Keeps Buy Rating MT
Ladenburg Thalmann Downgrades SAB Biotherapeutics to Neutral From Buy MT
HC Wainwright Adjusts SAB Biotherapeutics' Price Target to $2 From $4, Keeps Buy Rating MT
EF Hutton Initiates Coverage on Sonnet BioTherapeutics Holdings at Buy With $6.70 Price Target MT
Citigroup Initiates Sensei Biotherapeutics at Buy Rating MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $51 From $49, Maintains Overweight Rating MT
Goldman Sachs Downgrades Iovance Biotherapeutics to Neutral From Buy, Adjusts Price Target to $6 From $20 MT
HC Wainwright Starts SAB Biotherapeutics at Buy With $4 Price Target MT
Chardan Research Adjusts SAB Biotherapeutics' Price Target to $3 From $7, Maintains Buy Rating MT
Chardan Capital Adjusts SAB Biotherapeutics' Price Target to $7 from $10, Keeps Buy Rating MT
Chardan Adjusts SAB Biotherapeutics Price Target to $10 From $17, Maintains Buy Rating MT
Northland Securities Adjusts SAB Biotherapeutics PT to $21 From $18, Maintains Outperform Rating MT
Chardan Initiates SAB Biotherapeutics at Buy Rating With $17 Price Target on Medical Platform Potential MT
Baird Starts SAB Biotherapeutics at Outperform With $23 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.03 USD
Average target price
15.5 USD
Spread / Average Target
+284.62%
High Price Target
25 USD
Spread / Highest target
+520.35%
Low Price Target
6 USD
Spread / Lowest Target
+48.88%

Consensus detail

Consensus revision (last 18 months)

Analysts covering SAB Biotherapeutics, Inc.

HC Wainwright
Ladenburg Thalmann
Chardan Research
Northland Securities
Chardan
Baird

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SABS Stock
  4. Consensus SAB Biotherapeutics, Inc.